Transcriptomic characterization of the melanoma ecosystem before and early during immune checkpoint inhibition

Immune checkpoint inhibition (ICI) has become a standard of care in the treatment of advanced melanoma, and is increasingly used in treatment-naïve patients. While ICI is particularly successful in some patients, more than half will not obtain a durable response. The identification of predictive biomarkers and the elucidation of resistance mechanisms remain key challenges in immune-oncology today. We initiated a single-center, non-interventional study to profile the transcriptomic landscape of melanoma and its tumor environment at single cell resolution, before and early during treatment with anti-PD1 based ICI.